Promising renoprotective effect of gold nanoparticles and dapagliflozin in diabetic nephropathy via targeting miR‐192 and miR‐21

Abstract

Diabetic nephropathy (DN) is a worldwide issue that eventually leads to end‐stage renal failure, with limited therapeutic options. Prior research has revealed that gold nanoparticles (AuNPs) have a substantial antidiabetic impact. In addition, sodium‐glucose cotransporter2 (SGLT2) inhibitors, including dapagliflozin (DAPA), had renoprotective impact on DN. Therefore, this research attempted to determine the potential AuNPs and DAPA impacts in ameliorating experimentally DN induction and the underlying mechanisms focusing on miR‐192 and miR‐21, correlating them with autophagy, apoptosis, fibrosis, and oxidative stress. Diabetes induction was through a single intraperitoneal streptozotocin (55 mg/kg) injection, and rats with diabetes received AuNPs (2.5 mg/kg/day) as well as DAPA (2 mg/kg/day) for 7 weeks as a treatment. AuNPs and DAPA treatment for 7 weeks substantially alleviated DN. AuNPs and DAPA significantly increased catalase (CAT) activity as well as serum total antioxidant capacity (TAC), along with a substantial decline in malondialdehyde (MDA). AuNPs and DAPA treatment alleviated renal fibrosis as they decreased transforming growth factorß1(TGF‐ß1) as well as matrix metalloproteinase‐2 (MMP‐2) renal expression, decreased apoptosis through alleviating the proapoptotic gene (caspase‐3) renal expression and increased the antiapoptotic gene (Bcl‐2) renal expression, and increased autophagy as they increased LC‐3 as well as Beclin‐1 renal expression. Autophagy activation, inhibition of apoptosis, and renal fibrosis could be due to their inhibitory impact on miR‐192 and miR‐21 renal expression. AuNPs and DAPA have a protective effect on DN in rats by targeting miR‐192 and miR‐21 and their downstream pathways, including fibrosis, apoptosis, autophagy, and oxidative stress.